stockrowNewAmsterdam Pharma Company N.V. (NAMS) vs Septerna, Inc. (SEPN)
- NewAmsterdam Pharma Company N.V. NAMS 19.02 +0.69%
- Septerna, Inc. SEPN 48.95 +3.38%
NewAmsterdam Pharma Company N.V. and Septerna, Inc. are both Biotechnology companies. NewAmsterdam Pharma Company N.V. and Septerna, Inc. are of similar size ($2.3B and $2.2B). Septerna, Inc. grew revenue faster over the last twelve months: 13,520.1% against −26.4%. Septerna, Inc. has the higher net margin (−24.5% vs −789.9%) and the higher return on invested capital (−189.0% vs −13,975.8%). Across the 15 metrics below, Septerna, Inc. leads on 12 and NewAmsterdam Pharma Company N.V. on 3.
Valuation
Profitability
| Metric | NAMS | SEPN | Biotechnology median |
|---|---|---|---|
| Gross margin | 100.00% | 100.00% | 68.51% |
| Operating margin | (900.07%) | (44.04%) | 0.00% |
| Net margin | (789.94%) | (24.51%) | 0.00% |
| Free cash flow margin | (581.64%) | 118.93% | 0.00% |
| Return on equity | (30.16%) | (6.34%) | (51.96%) |
| Return on assets | (27.79%) | (4.94%) | (46.06%) |
| Return on invested capital | (13,975.75%) | (189.01%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack